Panacea Biotec Overview

  • Year Founded
  • 1984

Year Founded

  • Status
  • Public

  • Employees
  • 2,360

Employees

  • Stock Symbol
  • 531349

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $3.60
  • (As of Friday Closing)

Panacea Biotec General Information

Description

Panacea Biotec Ltd research-based biotechnology company engaged in the business of research, development, manufacture, and marketing of vaccines in India and international markets. Through its subsidiary company, the company is engaged in the business of research, development, manufacture and marketing of branded pharmaceutical formulations and nutritional products in India and international markets. The company's reportable segments are: a. Vaccines, b. Pharmaceutical formulations & Nutrition. It generates maximum revenue from the Vaccines segment. The company has a business presence in India and Outside India, with the maximum revenue derived from the overseas market.

Contact Information

Formerly Known As
Panacea Drugs
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • B-1 Extension G-3
  • Mohan Co-operative Industrial Estate, Mathura Road
  • New Delhi, Delhi 110044
  • India
+91 011
Primary Industry
Pharmaceuticals
Stock Exchange
BOM
Corporate Office
  • B-1 Extension G-3
  • Mohan Co-operative Industrial Estate, Mathura Road
  • New Delhi, Delhi 110044
  • India
+91 011

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Panacea Biotec Stock Performance

As of 20-Nov-2026, Panacea Biotec’s stock price is $3.60. Its current market cap is $220M with 61.1M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.60 $3.78 $3.09 - $6.77 $220M 61.1M 5K -$0.01

Panacea Biotec Financials Summary

As of 30-Jun-2026, Panacea Biotec has a trailing 12-month revenue of $74.2M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 354,534 179,795 293,383 69,104
Revenue 74,229 69,029 58,256 66,669
EBITDA 3,154 3,049 2,611 3,921
Net Income (786) (609) (990) (142)
Total Assets 133,772 150,778 148,791
Total Debt 0 1,590 1,754 1,799
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Panacea Biotec Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Panacea Biotec‘s full profile, request access.

Request a free trial

Panacea Biotec Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Panacea Biotec Ltd research-based biotechnology company engaged in the business of research, development, manufacture, a
Pharmaceuticals
New Delhi, India
2,360 As of 2026

Bengaluru, India
 

Mumbai, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Panacea Biotec Competitors (37)

One of Panacea Biotec’s 37 competitors is Biocon, a Formerly PE-Backed company based in Bengaluru, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biocon Formerly PE-Backed Bengaluru, India
Glenmark Pharmaceuticals Corporation Mumbai, India
Zydus Lifesciences Corporation Ahmedabad, India
Sun Pharmaceutical Industries Corporation Mumbai, India
Alkem Laboratories Formerly PE-Backed Mumbai, India
You’re viewing 5 of 37 competitors. Get the full list »

Panacea Biotec Patents

Panacea Biotec Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4812183-A1 Immunogenic composition of haemophilus influenzae conjugated to protein d Pending 21-Nov-2023
WO-2025109417-A1 Immunogenic composition of haemophilus influenzae conjugated to protein d Inactive 21-Nov-2023
EP-3355916-A1 Stable live attenuated recombinant dengue vaccine Pending 30-Sep-2015
EP-3355916-A4 Stable live attenuated recombinant dengue vaccine Pending 30-Sep-2015
US-11123420-B2 Stable live attenuated recombinant dengue vaccine Active 30-Sep-2015 A61K39/12
To view Panacea Biotec’s complete patent history, request access »

Panacea Biotec Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Panacea Biotec Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Panacea Biotec‘s full profile, request access.

Request a free trial

Panacea Biotec Investments (1)

Panacea Biotec’s most recent deal was a Later Stage VC with Cambridge Biostability for . The deal was made on 06-Dec-2006.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cambridge Biostability 06-Dec-2006 Later Stage VC Biotechnology
To view Panacea Biotec’s complete investments history, request access »

Panacea Biotec ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Panacea Biotec’s complete esg history, request access »

Panacea Biotec Exits (1)

Panacea Biotec’s most recent exit was on 06-Dec-2006 from Cambridge Biostability. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Cambridge Biostability 06-Dec-2006 Completed
To view Panacea Biotec’s complete exits history, request access »

Panacea Biotec FAQs

  • When was Panacea Biotec founded?

    Panacea Biotec was founded in 1984.

  • Where is Panacea Biotec headquartered?

    Panacea Biotec is headquartered in New Delhi, India.

  • What is the size of Panacea Biotec?

    Panacea Biotec has 2,360 total employees.

  • What industry is Panacea Biotec in?

    Panacea Biotec’s primary industry is Pharmaceuticals.

  • Is Panacea Biotec a private or public company?

    Panacea Biotec is a Public company.

  • What is Panacea Biotec’s stock symbol?

    The ticker symbol for Panacea Biotec is 531349.

  • What is the current stock price of Panacea Biotec?

    As of 20-Nov-2026 the stock price of Panacea Biotec is $3.60.

  • What is the current market cap of Panacea Biotec?

    The current market capitalization of Panacea Biotec is $220M.

  • What is Panacea Biotec’s current revenue?

    The trailing twelve month revenue for Panacea Biotec is $74.2M.

  • Who are Panacea Biotec’s competitors?

    Biocon, Glenmark Pharmaceuticals, Zydus Lifesciences, Sun Pharmaceutical Industries, and Alkem Laboratories are some of the 37 competitors of Panacea Biotec.

  • What is Panacea Biotec’s annual earnings per share (EPS)?

    Panacea Biotec’s EPS for 12 months was -$0.01.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process